Dr. Vogelzang on Mortalities in the Cabozantinib Trial

Video
Conference|ASCO Annual Meeting

Dr. Vogelzang from the Comprehensive Cancer Centers of Nevada discusses mortalities in cabozantinib trial.

Nicholas J. Vogelzang, MD, head of the Genitourinary Cancer Program at the Comprehensive Cancer Centers of Nevada discusses the 6 mortalities in the cabozantinib (XL184) phase II randomized discontinuation trial for patients with advanced solid tumors.

Related Videos
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Eric S. Christenson, MD
Samer A. Srour, MB ChB, MS
Rebecca L. Porter, MD, PhD
Deborah J. Wong, MD, PhD
Michael R. Migden, MD
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Related Content
Idalid Franco, MD, MPH, director of Equity Access and Inclusion in the Department of Radiation Oncology at Brigham and Women’s Hospital and an instructor at Harvard Medical School, both in Boston, Massachusetts

Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer

April 20th 2024
Article
R. Lor Randall, MD, FACS, of UC Davis Comprehensive Cancer Center

As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority

April 19th 2024
Article
Corey S. Cutler, MD, MPH, FRCPC, Dana-Farber Cancer Institute

Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD

April 17th 2024
Article
Richard Maziarz, MD, medical director, Blood & Marrow Transplant & Cellular Therapy Program, Oregon Health and Science University

Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma

April 16th 2024
Article
Thomas Powles, MD, MBBS, MRCP

Serial ctDNA Testing Could Improve Risk Stratification in High-Risk MIBC

April 16th 2024
Article
Matthew Galsky, MD

Adjuvant Nivolumab Provides Sustained DFS Benefit, Favors OS in Muscle-Invasive Urothelial Cancer

April 16th 2024
Article